Evidence map›Paper›PMID 32571981›Full record

ArticleMolecular cancer research : MCR2020

SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth.

Ikrame Lazar, Bertrand Fabre, Yongmei Feng, Ali Khateb, Patrick Turko, Julia M Martinez Gomez, Dennie T Frederick, Mitchell P Levesque, Lea Feld, Gao Zhang and 14 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 8 institutions in 5 countries.

Ikrame LazarSanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Bertrand Fabre *Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Yongmei Feng *Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Ali KhatebSanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Patrick TurkoDepartment of Dermatology, University Hospital of Zurich, Zurich, Switzerland.ORCID 0000-0003-3695-8264
Julia M Martinez GomezDepartment of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
Dennie T FrederickMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Mitchell P LevesqueDepartment of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
Lea FeldTechnion Integrated Cancer Center, Faculty of Medicine, Technion Institute of Technology, Haifa, Israel.
Gao ZhangThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0001-8617-8886
Tongwu ZhangLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.ORCID 0000-0003-2124-2706
Brian JamesSanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Jeny ShkloverTechnion Integrated Cancer Center, Faculty of Medicine, Technion Institute of Technology, Haifa, Israel.
Emily Avitan-HershTechnion Integrated Cancer Center, Faculty of Medicine, Technion Institute of Technology, Haifa, Israel.ORCID 0000-0002-2154-7609
Ido LivnehTechnion Integrated Cancer Center, Faculty of Medicine, Technion Institute of Technology, Haifa, Israel.
Marzia ScortegagnaSanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Kevin BrownLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
Ola LarssonDepartment of Oncology-Pathology, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.
Ivan TopisirovicLady Davis Institute, Sir Mortimer B. Davis Jewish General Hospital, Gerald Bronfman Department of Oncology, Departments of Experimental Medicine and Biochemistry, McGill University, Montreal, Quebec, Canada.ORCID 0000-0002-5510-9762
Haguy WolfensonTechnion Integrated Cancer Center, Faculty of Medicine, Technion Institute of Technology, Haifa, Israel.ORCID 0000-0001-6892-7839
Meenhard HerlynThe Wistar Institute, Philadelphia, Pennsylvania.
Keith FlahertyMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Reinhard DummerDepartment of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
Ze'ev A RonaiSanford Burnham Prebys Medical Discovery Institute, La Jolla, California. ronai@sbpdiscovery.org.
Technion – Israel Institute of Technology · ILDiscovery Institute · USUniversity Hospital of Zurich · CHCancer Genetics (United States) · USMassachusetts General Hospital · USThe Wistar Institute · USJewish General Hospital · CAScience for Life Laboratory · SE

Funding

Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2M
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
Targeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2008 to 2023
$37.1M
Research Project 2 - Targeting Melanoma Tumor Survival and Apoptotic MachineryU54CA224070 · NCI · WISTAR INSTITUTE · PI Michael Davies, Meenhard F Herlyn · 2017 to 2026
$13.9M
Targeted Combination Therapy for MelanomaP50CA174523 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2014 to 2018
$11.1M
Rewired Signaling at the Nexus of Melanoma Metastasis and ResistanceR35CA197465 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI RONAI, ZEEV A. · 2016 to 2022
$7.9M
Control of Protein Synthesis by the UPS Under StressR01CA202021 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI RONAI, ZEEV A. · 2016 to 2020
$2.3M
NCI NIH HHS P01 CA114046NCI NIH HHS P30 CA010815NCI NIH HHS P30 CA030199NCI NIH HHS P50 CA174523NCI NIH HHS R01 CA202021NCI NIH HHS R35 CA197465NCI NIH HHS U54 CA224070
6 · The paper itself

Abstract

Mechanisms regulating nuclear organization control fundamental cellular processes, including the cell and chromatin organization. Their disorganization, including aberrant nuclear architecture, has been often implicated in cellular transformation. Here, we identify Lamin A, among proteins essential for nuclear architecture, as SPANX (sperm protein associated with the nucleus on the X chromosome), a cancer testis antigen previously linked to invasive tumor phenotypes, interacting protein in melanoma. SPANX interaction with Lamin A was mapped to the immunoglobulin fold-like domain, a region critical for Lamin A function, which is often mutated in laminopathies. SPANX downregulation in melanoma cell lines perturbed nuclear organization, decreased cell viability, and promoted senescence-associated phenotypes. Moreover, SPANX knockdown (KD) in melanoma cells promoted proliferation arrest, a phenotype mediated in part by IRF3/IL1A signaling. SPANX KD in melanoma cells also prompted the secretion of IL1A, which attenuated the proliferation of naïve melanoma cells. Identification of SPANX as a nuclear architecture complex component provides an unexpected insight into the regulation of Lamin A and its importance in melanoma. IMPLICATIONS: SPANX, a testis protein, interacts with LMNA and controls nuclear architecture and melanoma growth.

Indexed as

HumansLaminsLamin Type AMelanomaNuclear ProteinsTransfectionlamin C protein, humanLaminsLamin Type ANuclear Proteins

Identifiers

PMID32571981
PMCPMC7541784
OpenAlexW3036138442

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.